Atossa Therapeutics Newsroom

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsDec 12 12:31 ET

Atossa Therapeutics Analyst Ratings

BenzingaDec 12 12:26 ET

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsDec 12 08:31 ET

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsDec 11 15:31 ET

Atossa Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow JonesDec 9 05:02 ET

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 13 14:32 ET

Atossa Therapeutics Analyst Ratings

BenzingaNov 13 13:39 ET

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Raises Target Price to $7

Moomoo NewsNov 13 06:31 ET

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 6 12:32 ET

Atossa Therapeutics Analyst Ratings

BenzingaNov 5 09:32 ET

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsNov 4 10:31 ET

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 1 15:31 ET

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsOct 31 10:31 ET

Atossa Therapeutics Analyst Ratings

BenzingaSep 11 05:45 ET

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsAug 13 13:31 ET

Atossa Therapeutics Analyst Ratings

BenzingaJun 28 11:13 ET

Atossa Therapeutics Analyst Ratings

BenzingaJun 20 13:27 ET

Atossa Therapeutics Analyst Ratings

BenzingaJun 6 13:10 ET

Atossa Therapeutics' Endoxifen Shows Promising Phase 2 Results, Secures Buy Rating

TipRanksMay 14 13:40 ET

Atossa Therapeutics Analyst Ratings

BenzingaApr 16 11:04 ET